Last Update: Jul 30, 2026 A Multicenter Open-label Extension Study to Evaluate Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients. ClinicalTrials.gov Identifier: [NCT07543120](https://clinicaltrials.gov/ct2/show/NCT07543120) Novartis Reference Number:CQCZ484A12203B [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols. This is a single arm, multicenter, OLE study designed to evaluate long-term safety, tolerability and efficacy of QCZ484, administered SC, once Q6M, in patients with HTN, who have successfully completed treatment period in the parent studies of the QCZ484 HTN program. Participants at sites from the parent study will be offered the option to enroll in this extension study at the Month 12 visit upon successful completion of the parent study treatment. Condition Hypertension (HTN) Phase Phase2 Overall Status Recruiting Number of Participants323 Start Date May 07, 2026 Completion Date Nov 30, 2031 Gender All Age(s) 18 Years - (Adult, Older Adult) ## Interventions Drug ### QCZ484 QCZ484 subcutaneous injection, Q6M. ## Eligibility Criteria Inclusion Criteria: 1\. Signed informed consent must be obtained prior to participation in the study. 2\. Successful completion of treatment period on QCZ484 study medication in parent study. 3\. No significant safety issue that may place participant at safety risk as determined by the Investigator. Exclusion Criteria: Participants meeting any of the following criteria, may it be pre-existing or developed during the parent study, are not eligible for inclusion in this study: 1\. Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator. 2\. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study. 3\. Permanent or persistent atrial fibrillation developed during the parent study. 4\. Clinically significant valvular heart disease developed during the parent study. 5\. Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to enrollment. Other protocol-defined inclusion/exclusion criteria may apply Japan #### Novartis Investigative Site Recruiting Chuo-ku,Tokyo,1030027,Japan #### Novartis Investigative Site Recruiting Chuo Ku,Tokyo,104-0031,Japan #### Novartis Investigative Site Recruiting Shinjuku Ku,Tokyo,160-0008,Japan #### Novartis Investigative Site Recruiting Suita,Osaka,5650853,Japan Singapore #### Novartis Investigative Site Recruiting Singapore,529889,Singapore #### Novartis Investigative Site Recruiting Singapore,119074,Singapore United States #### Alliance for Multispecialty Research Recruiting Wichita,Kansas,67207,United States ###### Jerry Punch ###### Layla Maxwell Email: #### American Research Centers of FL Recruiting Pembroke Pines,Florida,33027,United States ###### Luis Del Prado Rodriguez ###### Liliana Portal Email: #### Cen Exel FCR Recruiting Tampa,Florida,33613,United States ###### Deborah White ###### Kaylie Locascio Email: #### Sun Research Institute Recruiting San Antonio,Texas,78205,United States ###### Leonel Reyes ###### Chandana Gagireddy Email: #### Clinical Neuroscience Solutions Inc Recruiting Memphis,Tennessee,38119,United States ###### Melissa Flowers Phone: [+1 901 843 1045]() Email: ###### Lora J. McGill #### Eagle Clinical Research Recruiting Chicago,Illinois,60621,United States ###### Iesha Griffin Email: ###### Olalekan Sowade #### Oakland Medical Research Center Recruiting Troy,Michigan,48085,United States ###### Jay Sandberg ###### Julie Lafave Phone: [+1 248 828 7500]() Email: #### Clinical Research of Brandon LLC Recruiting Brandon,Florida,33511,United States ###### Erika Santos Email: ###### German Alvarez #### CenExel HRI Recruiting Berlin,New Jersey,08009,United States ###### Danielle Brudon Phone: [+1 856 452 9901#802]() Email: ###### Kyle Coupe #### Conrad Clinical Research Recruiting Edmond,Oklahoma,73013,United States ###### Shelly Todd Email: ###### Vicki Conrad #### Monroe Biomedical Research Recruiting Monroe,North Carolina,28112,United States ###### Awawu Igbinadolor ###### Maya Patterson Phone: [+1 704 283 7359]() Email: #### NICRs Research Center Recruiting Garden Grove,California,92844,United States ###### Maria Murillo Phone: [+1 909 206 2454]() Email: ###### Mallu Reddy #### Entrust Clinical Research Recruiting Miami,Florida,33176,United States ###### Adolfo Cueli ###### Daimelys Garcia Email: #### Inpatient Research Clinical LLC Recruiting Miami Lakes,Florida,33014,United States ###### Alexis Gutierrez ###### Ilianys Marino Phone: [+1 786 502 4303]() Email: #### Javara Research Recruiting Fayetteville,Georgia,30214,United States ###### Shemeka Williams Phone: [229 518 4947]() Email: ###### William Cooper #### Anderson Medical Research Recruiting Ft. Washington,Maryland,20744,United States ###### Ann-Marie Cobb Email: ###### Felton Anderson #### Downtown L A Research Center Inc Recruiting Los Angeles,California,90017,United States ###### Claudia Cisneros Phone: [+1 213 261 3680]() Email: ###### Salil U Nadkarni #### Cardiology Partners Clinical Research Institute Recruiting Wellington,Florida,33449,United States ###### Hiromi Hauserman Phone: [+1 561 537 4778]() Email: ###### Neerav Suresh Shah #### Jefferson City Medical Group Recruiting Jefferson City,Missouri,65109,United States ###### George Carr ###### Suzin Cunningham Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: [](mailto:) #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: